Loading...
XNAS
SAVA
Market cap57mUSD
, Last price  
USD
Name

Cassava Sciences Inc

Chart & Performance

D1W1MN
XNAS:SAVA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
13.09%
Rev. gr., 5y
%
Revenues
0k
53,918,00065,984,00063,725,00020,563,00016,809,00011,484,00010,890,00041,119,000000000000000
Net income
-91m
L+273.73%
6,188,00020,305,00015,347,000-3,467,000-12,023,000-2,613,000-3,446,00031,544,000-12,386,000-14,145,000-14,850,000-11,911,000-6,557,000-4,631,000-6,334,000-32,385,000-76,246,000-97,217,000-24,342,000-90,973,000
CFO
-32m
L-72.42%
-11,827,0002,231,00011,163,000-14,691,000-143,000-260,000-7,171,000-6,947,000-9,549,000-9,053,000-12,234,000-8,237,000-4,770,000-2,514,000-5,382,000-30,196,000-77,514,000-82,025,000-116,929,000-32,252,000
Dividend
Dec 13, 20120.75 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc.
URL
https://www.cassavasciences.com/
IPO date
Jul 14, 2000
Employees
26
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT